Altamira Therapeutics Ltd... (CYTO)
Altamira Therapeutics Statistics
Share Statistics
Altamira Therapeutics has 3.78M shares outstanding. The number of shares has increased by 68.67% in one year.
| 3.78M |
| 68.67% |
| 0% |
| 3.13% |
| n/a |
| 7,891 |
| 5.59% |
Short Selling Information
| n/a |
| n/a |
| n/a |
| n/a |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is null. Altamira Therapeutics's PEG ratio is 0.
| -0.2 |
| n/a |
| 0 |
| 0.2 |
| 0.22 |
| -0.12 |
| 0 |
Enterprise Valuation
Altamira Therapeutics has an Enterprise Value (EV) of 918.84K.
| 0 |
| -0.68 |
| -0.08 |
| -0.08 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.02.
| 1.38 |
| 1.38 |
| 0.02 |
| -0.07 |
| -0.01 |
| 0 |
Financial Efficiency
Return on Equity is -112.56% and Return on Invested Capital is -85.68%.
| -112.56% |
| -94.49% |
| -85.68% |
| n/a |
| $-727,003.8 |
| 10 |
| 0 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by -79.17% in the last 52 weeks. The beta is 2.44, so Altamira Therapeutics's price volatility has been higher than the market average.
| 2.44 |
| -79.17% |
| 0.23 |
| 0.81 |
| 46.38 |
| 141,045 |
Balance Sheet
The company has 617.41K in cash and 99.66K in debt, giving a net cash position of 517.75K.
| 617.41K |
| 99.66K |
| 517.75K |
| -18.05M |
| 7.69M |
| 334.24K |
Cash Flow
In the last 12 months, operating cash flow was -11.51M and capital expenditures 0, giving a free cash flow of -11.51M.
| -11.51M |
| n/a |
| -11.51M |
| -23.44 |
Margins
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Dividends & Yields
CYTO does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| -506.06% |
| -801.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Stock Splits
The last stock split was on Dec 13, 2023. It was a backward split with a ratio of 1:20.
| Dec 13, 2023 |
| backward |
| 1:20 |
Scores
| -3.85 |
| 3 |